Muromonab-CD3
- Atc Codes:L04AA02
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Orthoclone OKT3; France: Orthoclone OKT3; Germany: Orthoclone OKT3; Italy: Orthoclone OKT3; Luxembourg: Orthoclone OKT3; Netherlands: Orthoclone OKT3; Portugal: Orthoclone OKT3.
North America
Canada: Orthoclone OKT3; USA: Orthoclone OKT3.
Latin America
Brazil: Orthoclone OKT3; Mexico: Ior-T3, Orthoclone OKT3.
Asia
Japan: Orthoclone OKT3.
Drug combinations
Chemistry
Muromonab-CD3: A biochemically purified IgG~2α~ immunoglobulin consisting of a heavy chain of approximately 50000 daltons and a light chain of approximately 25000 daltons. Manufactured by a process involving fusion of mouse myeloma cells to lymphocytes from immunized animals to produce a hybridoma which secretes antigen-specific antibodies to T3 antigen of human T-lymphocytes (1989).
Pharmacologic Category
Immunosuppressive Agents. (ATC-Code: L04AA02).
Mechanism of action
Reverses graft rejection by binding to T cells and interfering with their function by binding T-cell receptor-associated CD3 glycoprotein.
Therapeutic use
Treatment of acute allograft rejection in renal transplant patients. Treatment of acute hepatic and kidney rejection episodes resistant to conventional treatment.
Pregnancy and lactiation implications
Use with caution during pregnancy or lactation.
Unlabeled use
Treatment of acute pancreas rejection episodes resistant to conventional treatment.
Contraindications
Hypersensitivity to OKT3 or any murine product. Uncompensated heart failure or uncontrolled hypertension, in fluid overload or patients with >3% weight gain within 1 week prior to start of OKT3. Mouse antibody titers >1:1000. History of seizures. Known or suspected pregnancy. Breast-feeding.
Warnings and precautions
Anaphylactic and anaphylactoid reactions may occur. Acute hypersensitivity reactions (cardiovascular collapse, cardiorespiratory arrest, loss of consciousness, shock, tachycardia, tingling, angioedema, airway obstruction, bronchospasm, dyspnea, urticaria, and pruritus). CNS events (seizures, encephalopathy, cerebral edema, aseptic meningitis, and headache) reported. Contraindicated for use in history of seizures or patients predisposed to seizures. Cytokine release syndrome may occur following first couple of doses. Possible increased susceptibility to infection. Increased risk of development of lymphoproliferative disorders (particularly of skin). Severe pulmonary edema occurred with fluid overload. Arterial, venous, and capillary thrombosis of allografts and other vascular beds reported (use with caution in history of thrombosis or underlying vascular disease). May result in an increased susceptibility to infection.